Co-Diagnostics (NASDAQ:CODX) Posts Quarterly Earnings Results

Co-Diagnostics (NASDAQ:CODX) released its earnings results on Thursday. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.02), Zacks reports. Co-Diagnostics had a negative return on equity of 54.94% and a negative net margin of 563.93%.

Co-Diagnostics Stock Down 6.4 %

Shares of CODX traded down $0.03 during mid-day trading on Thursday, reaching $0.39. The company’s stock had a trading volume of 705,748 shares, compared to its average volume of 181,234. The company has a market cap of $12.45 million, a price-to-earnings ratio of -0.28 and a beta of 1.29. The business has a fifty day moving average of $0.63 and a 200 day moving average of $0.90. Co-Diagnostics has a 1 year low of $0.34 and a 1 year high of $2.23.

About Co-Diagnostics

Co-Diagnostics, Inc, a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting.